Creating medicines for immune-mediated disease based on Attobody®, a novel biparatopic nanobody platform.
11 - 50
💰 $60M Series A on 2023-06
2 days ago
🏢 In-office - Bay Area
⏰ Full Time
🟠 Senior
August 27
👷♀️ Project Manager
🚔 Compliance